Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes

Gain multidisciplinary expert insights on the latest approved AML therapies to improve the care of patients with newly diagnosed or relapsed/refractory disease with these downloadable slides and on-demand Webcast of a CCO/NCCN Webinar.

Share

Program Content

Activities

AML Without Targetable Tx
Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

AML With Targetable Tx
Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

New Therapies in AML
New and Novel Advances in AML Therapeutics
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

<i>EP</i>: AML Expert Guidance
ExpressPoints
Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2021

Expires: June 22, 2022

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

AbbVie Inc.

Astellas Pharma US

Pfizer, Inc.

Servier Pharmaceuticals